NPS play an increasingly important role in the diagnosis of NDD. Consensus diagnostic criteria have evolved for psychosis, depression, agitation, and apathy in NDD. With one exception-pimavanserin is approved for the treatment of hallucinations and delusions in Parkinson\'s disease-there are no drugs approved by the FDA for treatment of NPS in NDD. Trials show that atypical antipsychotics reduce psychosis in AD and in Parkinson\'s disease, although side effect concerns have constrained their use. Antidepressants show benefit in treatment of Parkinson\'s disease with depression. Several agents are in clinical trials for treatment of NPS in NDD. Neuropsychiatric syndromes play a major role in NDD diagnosis. Clinical criteria allow recognition of NPS in NDD. Psychotropic medications are often useful in the treatment of NPS in NDD; efficacious, safe, and approved agents are needed.
NPS在NDD的诊断中起着越来越重要的作用。精神病的共识诊断标准已经发展,抑郁症,激动,对NDD的冷漠。除了一个例外,匹马色林被批准用于治疗帕金森病的幻觉和妄想-FDA没有批准用于治疗NDD中NPS的药物。试验表明,非典型抗精神病药可减少AD和帕金森病的精神病,尽管副作用问题限制了它们的使用。抗抑郁药在帕金森病伴抑郁症的治疗中显示出益处。几种药物正在临床试验中用于治疗NDD中的NPS。神经精神综合征在NDD诊断中起主要作用。临床标准允许在NDD中识别NPS。精神药物通常可用于治疗NDD的NPS;有效的,安全,需要批准的代理人。